

FIG. 1

Patient no.	Sex ^a	Antiretroviral regimen ^b		Mo of HAART	CD4 cell count (cells/ μ l)	Plasma viral load (log ₁₀ eq copies/ml)
		Initial	Modification (mo ^c)			
1	M	Naive			247	4.85
2	M	Naive			262	4.62
3	F	Naive			302	4.24
4	M	Naive			374	5.14
5	M	Naive			395	4.88
6	M	Naive			415	4.21
7	F	Naive			421	4.38
8	M	Naive			467	5.22
9	F	Naive			541	4.39
10	M	Naive			557	5.01
11	M	3TC-d4T-IDV	None	40	332	<1.70
12	M	3TC-d4T-IDV	None	42	426	<1.70
13	F	3TC-d4T-IDV	None	40	441	<1.70
14	M	3TC-d4T-IDV	None	38	449	<1.70
15	M	3TC-d4T-IDV	None	41	483	<1.70
16	F	3TC-d4T-IDV	3TC-ZDV-IDV (1)	38	559	<1.70
17	M	3TC-d4T-IDV	3TC-ZDV-IDV (5)	43	566	<1.70
18	F	3TC-d4T-IDV	None	38	605	<1.70
19	M	3TC-d4T-IDV	None	40	612	<1.70
20	M	3TC-d4T-IDV	None	40	696	<1.70
21	M	3TC-d4T-IDV	None	39	311	5.44
22	M	3TC-d4T-IDV	3TC-ZDV-IDV (4)	41	385	4.26
23	M	3TC-d4T-IDV	3TC-d4T-RTV-SQV (6)	43	397	4.79
24	M	3TC-d4T-IDV	None	45	401	4.28
25	M	3TC-d4T-IDV	3TC-d4T-RTV-SQV (8)	42	409	5.87
26	M	3TC-d4T-IDV	3TC-d4T-RTV-SQV (8)	42	523	4.67
27	M	3TC-d4T-IDV	None	41	569	5.63
28	F	3TC-d4T-IDV	3TC-d4T-RTV-SQV (7)	44	646	5.18
29	M	3TC-d4T-IDV	3TC-ZDV-IDV (5)	42	654	4.47
30	M	3TC-d4T-IDV	3TC-ZDV-IDV (4)	41	672	5.15

^a M, male; F, female.

^b ZDV, zidovudine; 3TC, lamivudine; d4T, stavudine; IDV, didanosine; RTV, ritonavir; SQV, saquinavir.

^c Indicates the time after which the initial antiretroviral regimen was modified because of side effects of IDV or d4T.

FIG. 2A





FIG. 2B

FIG. 3A





FIG. 3B

FIG. 4B

Log HIV RNA copies/ml of culture supernatant




FIG. 4D

FIG. 4A

Log proviral HIV DNA copies/million of PBMC




FIG. 4C




FIG. 5A




FIG. 5B




FIG. 5C



FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D

FIG. 7A





FIG. 7B

FIG. 7C




FIG. 7D




FIG. 7E





FIG. 7F




FIG. 8A




FIG. 8B




FIG. 8C

VIRUS

Inventor: Louis Lu et al.

Sheet 13 of 16

Docket No.: 1187-R-02

Piper Rudnick LLP (215) 656-3381



FIG. 9A



FIG. 9B




FIG. 10A




FIG. 10B

Animal no.	Sex	Weight (kg)	CD4 ⁺ T cells/ μ l		Plasma SIV RNA log ₁₀ copies/ml		Immunization
			Day 0	Day 60	Peak (day 14)	Set point (day 60)	
Group A							
1	male	4.5	958	1172	7.99	5.31	AT-2-Inactivated SIV-loaded DC vaccine at weeks 0, 2, 4, 6, and 8
2	male	4.7	1151	803	7.83	5.27	
3	male	4.8	900	1192	7.02	5.70	
4	male	4.8	2316	906	7.09	5.71	
5	male	4.4	995	1081	6.95	5.22	
6	female	4.6	797	803	7.80	5.29	
7	female	5.2	1061	834	7.69	5.91	
8	female	5.0	1124	1267	7.46	5.27	
9	female	4.6	1092	918	8.13	5.14	
10	female	5.0	760	961	7.60	5.48	
Mean		4.8	1115	1034	7.56	5.43	
s.d.		0.2	442	169	0.39	0.24	
Group B							
11	male	4.7	1599	1523	7.51	5.27	unloaded autologous DCs at weeks 0, 2, 4, 6, and 8
12	male	4.9	733	829	7.43	5.00	
13	female	4.6	1380	953	7.88	5.21	
14	female	4.0	1071	689	7.71	5.75	
Mean		4.6	1196	999	7.63	5.31	
s.d.		0.3	326	317	0.18	0.27	

FIG. 11